Reuters logo
Novartis' Ultibro Breezhaler superior to GSK's Seretide in study
April 30, 2014 / 5:32 AM / 3 years ago

Novartis' Ultibro Breezhaler superior to GSK's Seretide in study

ZURICH, April 30 (Reuters) - Novartis’ inhaled medicine Ultibro Breezhaler for chronic lung disease was better at improving lung function than GlaxoSmithKline’s Seretide, the Swiss drugmaker said on Wednesday, citing a late stage study.

The Phase III study in patients with moderate chronic obstructive pulmonary disease (COPD) found Novartis’ once-daily drug improved lung function compared to GSK’s Seretide, which must be taken twice daily.

Reporting By Caroline Copley

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below